<DOC>
	<DOC>NCT00117286</DOC>
	<brief_summary>This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years.</brief_summary>
	<brief_title>Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer</brief_title>
	<detailed_description>Participants who completed the main FE200486 CS14 study initially continued with the same dose in the FE200486 CS14A extension study. A protocol amendment changed the dosage to 160 mg (40 mg/mL) for all study participants. The data include data from the participants who participated in both the main study (FE200486 CS14; NCT00116779) and the extension study FE200486 CS14A.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has given written consent prior to any studyrelated activity being performed. A studyrelated activity is defined as any procedure that would not have been performed during the normal management of the patient. Has completed study FE200486 CS14 through visit 22. Exclusion Criterion: Has been withdrawn from the FE200486 CS14 study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>